| Press Release | ||
| Nicox Analyst Coverage Initiated by Edison Investment Research | ||
| January 22, 2021 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise, has initiated equity research coverage of Nicox. The financial report by Edison, released on January 21, 2021, is available on the Edison website https://www.edisongroup.com/publication/focus-on-sight/28664 (https://www.edisongroup.com/publication/focus-on-sight/28664). Nicox is also covered by Bryan, Garnier & Co. and Kepler Cheuvreux in France, and H.C Wainwright & Co., Oppenheimer & Co. Inc. and Cantor Fitzgerald in the U.S. Michele Garufi, Chairman and CEO of Nicox, will present at the Edison Open House Global Healthcare Conference 2021 being held virtually on January 26-28, 2021. The video webcast of Nicox's presentation will be available on-demand by clicking here (https://www.lsegissuerservices.com/spark/healthcare-companies-presenting-edison-open-house) and accessible on Nicox's website (www.nicox.com (http://www.nicox.com)) in the "Presentations & Events" section. | ||
| About Nicox | ||
| Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com (http://www.nicox.com). | ||
| Analyst coverage | ||
| Bryan, Garnier & Co Victor Floc'h Paris, France Cantor Fitzgerald Louise Chen New York, U.S. Edison Pooya Hemami London, U.K. H.C. Wainwright & Co Yi Chen New York, U.S. Kepler Cheuvreux Damien Choplain Paris, France Oppenheimer & Co Hartaj Singh New York, U.S. | ||
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. | ||
| Contacts | ||
| Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T +33 (0)4 97 24 53 00 communications@nicox.com (mailto:communications@nicox.com) | ||
| Investors & Media United States & Europe LifeSci Advisors, LLC Mary-Ann Chang T +44 7483 284 853 mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com) | Media France LifeSci Advisors, LLC Sophie Baumont M +33 (0)6 27 74 74 49 sophie@lifesciadvisors.com (mailto:sophie@lifesciadvisors.com) | |
| Forward-Looking Statements | ||
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox's website (www.nicox.com (http://www.nicox.com)) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox's website.. | ||
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 | ||
Attachment
- EN_Edison Nicox Initiation PR_20210122_F1 (https://ml-eu.globenewswire.com/Resource/Download/5852def1-618d-4229-9483-709b84858320)
© 2021 GlobeNewswire (Europe)
